Clinical Trial Search

Primary: Percentage of Participants With Absence of Active Retinopathy of Prematurity (ROP) and Unfavorable Structural Outcomes From Baseline to Week 52 of Chronological Age…

Primary: Proportion of Participants With Absence of Active ROP and Unfavorable Structural Outcomes — 0.855; 0.821 Proportion of participants

Primary: Severity of Retinopathy of Prematurity (ROP) as Compared to the Severity of ROP in an Untreated Control Population — 14; 24; 4; 4 participants — p=0.0642

Primary: Percentage of Participants With Absence of Active ROP and Absence of Unfavorable Structural Outcomes in Both Eyes at Week 24 — 80.0; 75.0; 66.2 Percentage of…

Primary: Regression of Retinopathy of Prematurity (ROP) in Premature Infants by Propranolol Therapy — 4; 8 cases

Primary: Changes in mRNA Expression in Blood of STAT3, PPAR-ɣ, and STC-1 at T0 — 4.19; 7.58; 6.43; 11.32 delta Ct (amplification cycles) — p=0.22

Primary: Number of Participants With Successful Treatment of ROP — 11; 14; 21; 9 Participants

Primary: Rate of Retinal Attachment — 50; 42 Participants

Primary: Heart Rate — 154; 154; 152; 163 Beats per minutes

Primary: Number of Participants With Visual Acuity as Assessed by an Age-appropriate Method at 6 Months Corrected Age (CA) — 0; 0; 12; 19 Participants

Primary: Efficacy as Measured by the Number of Participants Presenting With Retinopathy of Prematurity (ROP) and the Rate of Stages/Grade of ROP. — 5; 3; 4; 1 Participants

Primary: Visual Acuity (VA) of the Better-seeing Eye at the Participant's Fifth Birthday Visit - Comparison Between Treatment Arms — 66.8; 64.6; 62.1 Score on a scale

Primary: Mean Change in Visual Acuity From Baseline — 2.8; 0.2 letters

Primary: Population Pharmacokinetics: V - Volume — 0.6572 l/kg

Primary: Number of Participants (or Chart Reviews) With Complete Success of Primary Vitrectomy Surgery — 92; 169 Participants

Primary: Full Scale IQ, Performance IQ, Verbal IQ, Executive Function — 79; 91; 103; 83 standardized score on a scale

Primary: Change in Electronic Early Treatment Diabetic Retinopathy Study Visual Acuity Letter Score From Baseline to 14 Weeks — -4; 1; 2 Letter Score — p=<.001

Primary: The Mean Percentage Change of the Area of the Patient's Neovascularization as Measured in Pixels by Optomap FA (Fluorescein Angiography) — -83.8; 52.6; 11.3; 55.4…

Primary: Composite Perinatal Morbidity — 277; 203; 221; 45 participants

Primary: Mean Change in Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuity at 104 Weeks From Day 0. — -1.9; -3.9; 1.3 letters

Primary: Intermittent Hypoxemia (IH) Events Per 8 Hours of Monitoring Time — 2.2; 1.2 IH events per 8 hours of monitoring time

Primary: Death or Neurodevelopmental Impairment — 423; 422; 422; 425 Participants — p=0.93

Primary: Mean Change in Cone Spacing in Arcminutes (Z Score) of 2 Baseline Values Were Compared With Measurements Obtained at Post-op Month 36 — 1.13; 0.85 Difference in change…

Primary: The Effect of an Anti-VEGF (Vascular Endothelial Growth Factor) Agent, Bevacizumab, on Levels of Vitreous and Aqueous Growth Factor Levels (pg/mL) in Eyes With Traction…

Primary: Rate of Resolved Post-operative Vitreous Hemorrhage. — 6; 5 Participants

Primary: Sensitivity(mtmDR) — 90.48; 95.65; 95.19 percentage of true positives

Primary: Best-corrected Visual Acuity — 52.9 ETDRS letters

Primary: Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0 — 0; 0; 0; 0 Participants

Primary: Duration of Home Oxygen Therapy — 66; 58 Days — p=<0.03

Primary: Per Patient Referral Accuracy — 318 Participants